Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
DEPO's Cash to Debt is ranked higher than
99% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. DEPO: No Debt )
DEPO' s 10-Year Cash to Debt Range
Min: 0.84   Max: No Debt
Current: No Debt

Equity to Asset 0.27
DEPO's Equity to Asset is ranked lower than
55% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.60 vs. DEPO: 0.27 )
DEPO' s 10-Year Equity to Asset Range
Min: -1.33   Max: 0.89
Current: 0.27

-1.33
0.89
Interest Coverage 1.73
DEPO's Interest Coverage is ranked lower than
56% of the 460 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 88.77 vs. DEPO: 1.73 )
DEPO' s 10-Year Interest Coverage Range
Min: 1.73   Max: 9999.99
Current: 1.73

1.73
9999.99
F-Score: 5
Z-Score: 1.63
M-Score: -1.65
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 6.94
DEPO's Operating margin (%) is ranked higher than
69% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.34 vs. DEPO: 6.94 )
DEPO' s 10-Year Operating margin (%) Range
Min: -12972.91   Max: 72.49
Current: 6.94

-12972.91
72.49
Net-margin (%) 32.27
DEPO's Net-margin (%) is ranked higher than
97% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. DEPO: 32.27 )
DEPO' s 10-Year Net-margin (%) Range
Min: -14964.35   Max: 75.05
Current: 32.27

-14964.35
75.05
ROE (%) 31.52
DEPO's ROE (%) is ranked higher than
99% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. DEPO: 31.52 )
DEPO' s 10-Year ROE (%) Range
Min: -361.88   Max: 108.13
Current: 31.52

-361.88
108.13
ROA (%) 8.52
DEPO's ROA (%) is ranked higher than
88% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.94 vs. DEPO: 8.52 )
DEPO' s 10-Year ROA (%) Range
Min: -201.21   Max: 61.03
Current: 8.52

-201.21
61.03
ROC (Joel Greenblatt) (%) 111.71
DEPO's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 732 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.50 vs. DEPO: 111.71 )
DEPO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2343.1   Max: 6607.29
Current: 111.71

-2343.1
6607.29
Revenue Growth (%) 15.60
DEPO's Revenue Growth (%) is ranked higher than
80% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. DEPO: 15.60 )
DEPO' s 10-Year Revenue Growth (%) Range
Min: -69.7   Max: 420.5
Current: 15.6

-69.7
420.5
EBITDA Growth (%) 46.00
DEPO's EBITDA Growth (%) is ranked higher than
94% of the 507 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. DEPO: 46.00 )
DEPO' s 10-Year EBITDA Growth (%) Range
Min: -55.8   Max: 84.2
Current: 46

-55.8
84.2
EPS Growth (%) 120.50
DEPO's EPS Growth (%) is ranked higher than
98% of the 510 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. DEPO: 120.50 )
DEPO' s 10-Year EPS Growth (%) Range
Min: -59.5   Max: 180.9
Current: 120.5

-59.5
180.9
» DEPO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2012

DEPO Guru Trades in Q4 2012

Steven Cohen 682 sh (New)
Paul Tudor Jones 18,700 sh (+39.55%)
» More
Q1 2013

DEPO Guru Trades in Q1 2013

Steven Cohen 8,395 sh (+1130.94%)
Paul Tudor Jones 43,000 sh (+129.95%)
» More
Q2 2013

DEPO Guru Trades in Q2 2013

Steven Cohen Sold Out
Paul Tudor Jones Sold Out
» More
Q4 2013

DEPO Guru Trades in Q4 2013

Jim Simons 129,338 sh (New)
Paul Tudor Jones 19,853 sh (New)
Steven Cohen 1,867,300 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with DEPO

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2012-06-30 Sold Out 0.01%$4.97 - $6.6 $ 12.87127%0
Daniel Loeb 2011-09-30 Sold Out 0.6154%$5 - $8.74 $ 12.8794%0
Joel Greenblatt 2011-09-30 Add 48.97%$5 - $8.74 $ 12.8794%15244
Daniel Loeb 2011-06-30 Reduce -34.52%0.46%$7.78 - $9.9 $ 12.8752%2030000
Joel Greenblatt 2011-06-30 New Buy0.01%$7.78 - $9.9 $ 12.8752%10233
Daniel Loeb 2011-03-31 Reduce -41.51%0.95%$5.66 - $10.02 $ 12.8758%3100000
George Soros 2011-03-31 Sold Out $5.66 - $10.02 $ 12.8758%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 17.10
DEPO's P/E(ttm) is ranked higher than
81% of the 528 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.60 vs. DEPO: 17.10 )
DEPO' s 10-Year P/E(ttm) Range
Min: 2.36   Max: 121.85
Current: 17.1

2.36
121.85
P/B 5.30
DEPO's P/B is ranked lower than
57% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.84 vs. DEPO: 5.30 )
DEPO' s 10-Year P/B Range
Min: 2   Max: 48.18
Current: 5.3

2
48.18
P/S 5.40
DEPO's P/S is ranked lower than
64% of the 722 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.99 vs. DEPO: 5.40 )
DEPO' s 10-Year P/S Range
Min: 1.38   Max: 530
Current: 5.4

1.38
530
PFCF 97.50
DEPO's PFCF is ranked lower than
58% of the 330 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.86 vs. DEPO: 97.50 )
DEPO' s 10-Year PFCF Range
Min: 2.37   Max: 113.33
Current: 97.5

2.37
113.33
EV-to-EBIT 50.00
DEPO's EV-to-EBIT is ranked lower than
62% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.45 vs. DEPO: 50.00 )
DEPO' s 10-Year EV-to-EBIT Range
Min: 0.4   Max: 130
Current: 50

0.4
130
Shiller P/E 97.40
DEPO's Shiller P/E is ranked lower than
65% of the 362 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.59 vs. DEPO: 97.40 )
DEPO' s 10-Year Shiller P/E Range
Min: 21.62   Max: 123.75
Current: 97.4

21.62
123.75

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 13.41
DEPO's Price/Tangible Book is ranked lower than
76% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.10 vs. DEPO: 13.41 )
DEPO' s 10-Year Price/Tangible Book Range
Min: 2.54   Max: 14.45
Current: 13.41

2.54
14.45
Price/DCF (Projected) 4.14
DEPO's Price/DCF (Projected) is ranked lower than
58% of the 346 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. DEPO: 4.14 )
DEPO' s 10-Year Price/DCF (Projected) Range
Min: 1.49   Max: 335
Current: 4.14

1.49
335
Price/Median PS Value 1.27
DEPO's Price/Median PS Value is ranked higher than
58% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.10 vs. DEPO: 1.27 )
DEPO' s 10-Year Price/Median PS Value Range
Min: 0.5   Max: 42.86
Current: 1.27

0.5
42.86
Price/Graham Number 3.17
DEPO's Price/Graham Number is ranked lower than
55% of the 461 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.20 vs. DEPO: 3.17 )
DEPO' s 10-Year Price/Graham Number Range
Min: 0.69   Max: 7.48
Current: 3.17

0.69
7.48
Earnings Yield (Greenblatt) 2.00
DEPO's Earnings Yield (Greenblatt) is ranked lower than
54% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. DEPO: 2.00 )
DEPO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.8   Max: 251.9
Current: 2

0.8
251.9
Forward Rate of Return (Yacktman) 0.53
DEPO's Forward Rate of Return (Yacktman) is ranked higher than
70% of the 532 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.45 vs. DEPO: 0.53 )
DEPO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -27.2   Max: 5.3
Current: 0.53

-27.2
5.3

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:DPO.Germany
Depomed, Inc. was incorporated in the State of California on August 7, 1995. The Company is a specialty pharmaceutical company that focuses on pain and other conditions and diseases of the central nervous system. Its products line encompasses Gralise, Zipsor, Glumetza, Janumet XR, and Proquin XR, among others. The core products comprises of Gralise, a once-daily product for the management of postherpetic neuralgia, and Zipsor liquid filled capsules, a product for the treatment of mild to moderate acute pain. It also has a portfolio of royalty and milestone producing assets based on its proprietary drug delivery technologies. A part of it is Glumetza, a once-daily treatment for adults with type 2 diabetes which is licensed and commercialized in the United States. It also has license and development arrangements for Acuform gastroretentive drug delivery technology with Covidien, Ltd., Boehringer Ingelheim International GMBH, Ironwood Pharmaceuticals, Inc., Merck & Co., Inc., Janssen Pharmaceutica N.V. and Janssen Pharmaceuticals, Inc. Further, it has two product candidates in clinical development, Serada and DM-1992. The Company derives revenues from the sale of its products, and from license fees, milestones and royalties earned on license agreements, as well as collaborative arrangements.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide